NATALEE
What it tests: Adjuvant ribociclib plus a nonsteroidal aromatase inhibitor in HR+/HER2− early breast cancer. Six-year overall survival and efficacy outcomes.
Videos
monarchEDESTINY-Breast05DESTINY-Breast11and 2 moreDr. Elisa AgostinettoBreast cancer: the picks from Berlin
Dr. Elisa Agostinetto. Expert pick. ESMO 2025.
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.